Doç. Dr. Dılşa Mızrak Kaya

• Makaleler (SCI/SCI-E, Ulusal Dergiler)

ARASTIRMA MAKALELERI

1. Mizrak Kaya D, Ma Y, Demir T, Kalyan A, Kircher S, Mulcahy M, Benson AB, Chen R, Mahalingam D. KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials. (under review)
2. Sahin TK, Eroglu I, Dilli I, Sutcuoglu O, Chalabiyev E, Guven DC, Aktas BY, Mizrak Kaya D, Ates O, Ozdemir N, Yalcin S, Dizdar O. Induction chemotherapy followed by definitive chemoradiation in patients with inoperable esophageal squamous cell carcinoma: a multicenter retrospective study. Discover Oncology. 2025 16(1).
3. Alkan A, Mizrak D, Yasar A, Karci E, Koksoy EB, Urun M, Ozyurt N, Kustas AA, Kutuk T, Urun Y, Senler Cay F, Akyurek S, Utkan G, Demirkazik A, Gokce SC, Akbulut H. Adjuvant Concurrent Chemoradiotherapy (CRT) plus Docetaxel-Cisplatin-Fluorouracil (DCF) versus CRT plus Fluorouracil-Folinic Acid (FUFA) in Stage III Gastric Cancer. Journal of Cancer Research and Therapeutics. 2024 20(3):913-917.
4. Duymus ME, Koseci T, Serindere M, Ceylan M, Bulgurcu A, Ipci O, Karadeniz C, Bag YM, Mizrak Kaya D. Patterns of multiple primaries in fortyfour cancer patients: a single-center clinical experience. Oncol Clin Pract. 2023; 19,1:28-33.
5. Yekeduz E, Dogan I, Mizrak Kaya D, Ozgur I, Utkan G, Vatansever S, Demirci S, Akbulut H, Urun Y. Systemic Immun-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study. Journal of Gastrointestinal Cancer. 2021 Nov: 1-10.
6. Mizrak Kaya D, Nogueras-Gonzalez GM, Harada K, Blum Murphy M, Lee JH, Bhutani MS, Weston B, Thomas I, Rogers JE, Das P, Badgwell BD, Ajani JA. Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. Oncology. 98(8):542-548.
7. Sonoda K, Samdani RT, Ikoma N, Mizrak Kaya D, Blum Murphy M, Ajani JA, Badgwell BD, Katz MH, Rashid A, Estrella JS. Gastric cancer in remnant stomach after pancreaticoduodenectomy: A case series. Journal of Surgical Oncology. 120(7), 1137-1141.
8. Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Annals of Surgery. 2020 Aug; 272(2):311-318.
9. Amlashi FG, Wang X, Davila RE, Maru DM, Bhutan MS, Lee JH, Weston BR, Mizrak Kaya D, Vassilakopoulou M, Harada K, Blum Murphy MA, Rice DC, Hofstetter WL, Davila M, Nguyen QN, Ajani JA. Barrett’s Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology. 2018;95(2):81-90. Doi: 10.1159/000488489.
10. Mizrak Kaya D, Nogueras-Gonzalez GM, Harada K, Amlashi FG, Thomas I, Rogers JE, Bhutani MS, Lee JH, Weston B, Minsky BD, Estrella JS, Blum Murphy M, Matamoros A, Devine CE, Das P, Badgwell BD, Ajani JA. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer. 2018 Jul;98:23-29. Doi: 10.1016/j.ejca.2018.04.012.
11. Mizrak Kaya D, Ozturk B, Kubilay P, Onur H, Utkan G, Cay Senler F, Alkan A, Yerlikaya H, Koksoy EB, Karci E, Demirkazik A, Akbulut H, Icli F. Diagnostic serum vitamin D level is not a reliable prognostic factor for early stage breast cancer. Future Oncol. 2018 Jun;14(15):1461-1467. Doi: 10.2217/fon-2017-0608.
12. Shimodaira Y, Slack RS, Harada K, Chen H-C, Sagebiel T, Bhutani MS, Lee J, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth J, Swisher S, Skinner H, Hofstetter W, Rogers J, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Influence of Induction Chemotherapy in Trimodality Therapy-Eligible Esophageal Cancer Patients: Secondary Analysis of a Randomized Trial. Br J Cancer. 2017 Dec 12; 118(3), 331-337.
13. Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA. Early metabolic change after induction chemotherapy predicts histologic response and prognosis in patients with esophageal cancer: Secondary analysis of a randomized trial. Targeted Oncology. 2017 Dec 7; 13(1), 99-106..
14. Mizrak Kaya D, Nogueras-Gonzalez GM, Harada K, Amlashi FG, Roy-Chowdhuri S, Estrella JS, Das P, Lee JH, Weston B, Bhutani MS, Matamoros A, Thomas I, Lin Q, Badgwell BD, Ajani JA. Risk of peritoneal metastases in patients who had negative peritoneal staginig and received therapy for localized gastric adenocarcinoma. J Surg Oncol. 2017 Dec 4; 117(4):678-684.
15. Elimova E, Slack R, Chen H-C, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS, Mizrak Kaya D, Sagebiel TL, Lee JH, Weston B, Bhutani M, Blum Murphy M, Matamaros A, Minsky B, Das P, Mansfield PF, Badgwell BD, Ajani JA. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget. 2017 Jul 13;8(46): 81430-81440. Doi: 10.18632/oncotarget.19226
16. Mizrak Kaya D, Dong X, Nogueras-Gonzalez GM, Xu Y, Estrella JS, Harada K, Lopez A, Amlashi FG, Hofstetter WL, Maru DM, Nguyen QN, Lee JH, Weston B, Bhutani MS, Erasmus JJ, Thomas I, Rogers JE, Song S, Ajani JA. Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. Med Oncol. 2017 Aug;34(8):1-7.
17. Wadhwa R, Wang X, Baladandayuthapani V, Liu B, Shiozaki H, Shimodaira Y, Lin Q, Elimova E, Hofstetter WL, Swisher SG, Rice DC, Maru DM, Kalhor N, Bhutani MS, Weston B, Lee JH, Skinner HD, Scott AW, Mizrak Kaya D, Harada K, Berry D, Song S, Ajani JA. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer. 2017 Aug 22;117(5):648-655. Doi: 10.1038/bjc.2017.225.
18. Mizrak Kaya D, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A Jr, Sagebiel T, Wu CC, Rogers JE, Thomas I, Maru DM, Skinner HD, Badgwell BD, Hofstetter WL, Ajani JA. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology. 2017;93(4):243-248. Doi:10.1159/000475550.
19. Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerkel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Mizrak Kaya D, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin Q, Ross WA, Weston B, Lee JH, Ajani JA. Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. Oncotarget. 2017 May 23;8(45):79256-79365. Doi: 10.18632/oncotarget.18119.
20. Shiozaki H, Slack RS, Chen HC, Elimova E, Planjery V, Charalampakis N, Wadhwa R, Shimodaira Y, Skinner H, Lee JH, Weston B, Bhutani MS, Blum-Murphy M, Rogers JE, Maru DM, Matamoros A Jr, Sagebiel T, Estrella JS, Das P, Hofstetter WL, Mares JE, Mizrak Kaya D, Harada K, Lin Q, Minsky BD, Badgwell BD, Ajani JA. Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. Oncology. 2016;91(1):55-60.
21. Alkan A, Guc ZG, Senler FC, Yavuzsen T, Onur H, Dogan M, Karci E, Yasar A, Koksoy EB, Tanriverdi O, Turhal S, Urun Y, Ozkan A, Mizrak D, Akbulut H. Breast cancer survivors suffer from persistent postmastectomy pain syndrome and posttraumatic stress disorder (ORTHUS study): a study of the palliative care working committee of the Turkish Oncology Group (TOG). Support Care Cancer. 2016 Sep;24(9):3747-55.
22. Arslan Sayki M, Turhan S, Dincer I, Mizrak D, Corapcioglu D, Idilman R. A potential link between endothelial function, cardiovascular risk, and metabolic syndrome in patients with Non-alcoholic fatty liver disease. Diabetol Metab Syndr. 2014 Oct 14;6(1) :1-6.
23. Yildiz G, Arslan-Ergul A, Bagislar S, Konu O, Yuzugullu H, Gursoy-Yuzugullu O, Ozturk N, Ozen C, Ozdag H, Erdal E, Karademir S, Sagol O, Mizrak D, Bozkaya H, Ilk HG, Ilk O, Bilen B, Cetin-Atalay R, Akar N, Ozturk M. Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis. PLoS One. 2013 May 15;8(5):e64016.
24. Karataylı SC, Alagöz SG, Mizrak D, Sayki M, Ozkan M, Savaş B, Erden E, Cinar K, Idilman R, Yurdaydın C, Bozdayi AM. Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS. Turk J Gastroenterol. 2012 Feb;23(1):46-53.
25. Idilman R, Bozkus Y, Seval G, Mizrak D, Cinar K, Ustun Y, Bektas M, Arat M, Akbulut H, Doganay B, Ozden A. Lymphoproliferative Disorders in Individuals with Chronic Hepatitis B and C in the Turkish Population. J Med Virol. 2011 Jun;83(6):974-80.
26. Mizrak D, Engin B, Onder FO, Yener B, Bektas M, Biyikli Z, Idilman R, Cinar K, Karayalcin K, Ozden A, Yurdaydin C, Yazihan N, Ataoglu H, Bozkaya H, Uzunalimoglu O. Aflatoxin exposure in viral hepatitis patients in Turkey. Turk J Gastroenterol. 2009 Sep;20(3):192-7.
27. Koytak ES, Mizrak D, Bektas M, Verdi H, Arslan Ergül A, Idilman R, Cinar K, Yurdaydin C, Ersoz S, Karayalcin K, Uzunalimoglu O, Bozkaya H. PPAR-alpha L162V polymorphism in human hepatocellular carcinoma. Turk J Gastroenterol. 2008 Dec;19(4):245-9.
28. Idilman R, Mizrak D, Corapcıoglu D, Bektas M, Doganay B, Saykı M, Coban S, Erden E, Soykan I, Emral R, Uysal AR, Ozden A. Clinical Trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008 Jul;28(2):200-8.

DERLEME MAKALELER

1. Mizrak D, Brittan M, Alison MR. CD 133: molecule of the moment. J Pathol. 2008 Jan;214(1):3-9.
2. Elimova E, Mizrak Kaya D, Harada K, Ajani JA. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clin Proc. 2016 Sep;91(9):1307-18.

1. Mizrak Kaya D, Harada K, Ajani JA. Is targeted therapy possible for patients with gastric adenocarcinoma? Expert Opin Pharmacother. 2016 Dec;17(18):2371-2374.
2. Harada K, Mizrak Kaya D, Shimodaira Y, Ajani JA. Global chemotherapy development for gastric cancer. Gastric Cancer. 2017 Mar;20 (Suppl 1):92-101
3. Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Proteomics approach to identify biomarkers for upper gastrointestinal cancer. Expert Rev Proteomics. 2016 Oct;13(11):1041-53.
4. Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Translating genomic profiling to gastrointestinal cancer treatment. Future Oncol. 2017 Apr;13(10):919-934.
5. Mizrak Kaya D, Harada K, Shimodaira Y, Amlashi FG, Lin Q, Ajani JA. Advanced gastric adenocarcinoma: optimizing therapy options. Expert Rev Clin Pharmacol. 2017 Mar;10(3):263-271.
6. Harada K, Mizrak Kaya D, Baba H, Ajani JA. Recent advances in preoperative management of esophageal adenocarcinoma. F1000Res. 2017 Apr 18;6:501.
7. Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. miRNA profile as a predictor of response to chemoradiation therapy for esophageal squamous cell carcinoma. Translational Cancer Research. 2016 Nov; 5(6S):S1204-S1207.
8. Mizrak Kaya D, Harada K, Ajani JA. Advances in therapeutic options for esophageal and esophagogastric junctional adenocarcinoma. Expert Opinion on Orphan Drugs. 2017 May;5(7). Doi: 10.1080/21678707.2017.1330146
9. Harada K, Mizrak Kaya D, Song S, Baba H, Ajani JA. Genomic profiling of colorectal cancers and the future of personalized treatment. Colorectal Cancer. 2017 June. 6(1): 11-22. Doi: 10.2217/crc-2016-0017
10. Lopez A, Harada K, Mizrak Kaya D, Ajani JA. Current therapeutic landscape for advanced gastroesophageal cancers. Ann Transl Med 2017; 6(4).
11. Harada K, Mizrak Kaya D, Lopez A, Baba H, Ajani JA. Personalized therapy based on image for esophageal or gastroesophageal junction carcinoma. Ann Transl Med 2017; 6(4).
12. Lopez A, Harada K, Mizrak Kaya D, Dong X, Song S, Ajani JA. Liquid biopsies in gastrointestinal malignancies: when is the big day? Expert Rev Anticancer Ther. 2018 Jan; 18(1):19-38.
13. Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA. Customization of therapy for gastroesophageal adenocarcinoma patients. Chronic Dis Transl Med. 2018 Mar 13;4(1):8-17. Doi: 10.1016/j.cdtm.2018.02.003.
14. Harada K, Mizrak Kaya D, Baba H, Ajani JA. Immune Checkpoint blockade therapy for esophageal squamous cell carcinoma. J Thorac Dis. 2018 Feb;10(2):699-702. Doi: 10.21037/jtd.2018.01.120.

VAKA TAKDIMLERI

1. Uckan D, Dogan M, Karagoz T, Mizrak D, Cetin M. A long-lasting hypotensive reaction associated with leukocytefiltered platelet transfusion in a post-bone marrow transplant patient with underlying severe cardiomyopathy. Pediatr Hematol Oncol. 2003 Oct-Nov;20(7):531-3.
2. Canbakan B, Mizrak D, Keven K, Kaygusuz G, Kutlay S, Sengul S, Erbay B. Gastric ulcer despite no acid in a renal allograft recipient: what is the link? Nephrol Dial Transplant. 2005 Oct;20(10):2279-81.
3. Mizrak D, Bektas M, Kaygusuz G, Cinar K, İdilman R, Ozden A. Gastric Aberrant Pancreas. Turk J Gastroenterol. 2010 Mar;21(1):68-9.
4. Tek I, Mizrak D, Utkan G, Toprak SK, Tutkak H, Buyukcelik A, Yalcin B, Akbulut H, Icli F. IgA lambda oligoclonal gammopathy in multiple myeloma. Turk J Hematol 2010 Jun 5;27(2):126-7.
5. Alkan A, Yucel L, Mizrak D, Akbulut H. Aflibercept-related nasal septum perforation. Asia-Pac J Clin Oncol. 2017 Apr;13(2):e179-e180.
6. Mizrak D, Alkan A, Erdogdu B, Utkan G. Osteogenesis imperfecta, pseudoachalasia, and gastric cancer. Case Rep Gastrointest Med. 2015;2015:685459. doi: 10.1155/2015/685459.
7. Dogan SE, Mizrak D, Alkan A, Demirkazik A. Docetaxel-induced pericardial effusion. J Oncol Pharm Pract. 2017 Jul;23(5):389-391.

MEKTUPLAR

1. Alkan A, Mizrak D, Utkan G. The more we use, the more we lose. Med Oncol. 2015 Apr;32(4):123.
2. Alkan A, Mizrak D, Utkan G. Lower folate levels in gastric cancer: Is it a cause or a result? World J Gastroenterol. 2015 Apr 7;21(13):4101-2.

DIGER YAYINLAR

1. Azap A, Yağcı D, Mizrak D, Toprak S. Images in Haematology. Turk J Haematology. 2004 Jun 5;21(2):111.
2. Mizrak D, Akbulut H. Cancer patient and hunger. Turkish Journal of Oncology. 2015;30(3):152-7. Doi: 10.5505/tjoncol.2015.1251.
3. Alkan A, Mizrak Kaya D, Ozgul S, Utkan G. Chemoembolization related mucosal melanosis. J Clin Exp Invest. 2015;6(2). Doi: 10.5799/ahinjs.01.2015.02.0515.
4. Alkan A, Koksoy EB, Mizrak Kaya D, Karci E, Yasar A, Utkan G. Adjuvant chemotherapy experience in solid pseudopapillary tumor of pancreas. International Journal of Advances in Case Reports. 2015;2(20):1249-51.
5. Mizrak Kaya D, Asfuroglu Kalkan E, Alkan A, Yerlikaya H, Koksoy EB, Karci E, Utkan G, Demirkazik A. An unexpected cause of hyponatremia in a cancer patient: Trimethoprim-sulfamethoxazole. Journal of Oncological Sciences. 2016. Doi: 10.1016/j.jons.2016.04.005.
6. Alkan A, Aksoy A, Mizrak Kaya D, Koksoy EB, Karci E, Utkan G, Demirkazik A. Tyroid follicular carcinoma complicating with skin metastasis. Journal of Oncological Sciences. 2016;2(2):82-3. Doi: 10.1016/j.jons.2016.09.003.
7. Alkan A, Mizrak Kaya D, Cay Senler F, Utkan G. Inadequate Nutritional Status of Hospitalized Cancer Patients. J Clin Exp Invest. 2017. Doi: 10.5799/ahinjs.01.2017.01.0616.
8. Bakar Ates F, Mizrak Kaya D. The Investigation of Relationship Between Annexin A1 Gene Expression and Inflammation in Colorectal Cancer Patients. Acta Oncologica Turcica. 2018;51(1):159-165. Doi: 10.5505/aot.2018.29591.
9. Koseci T, Haksoyler V, Karadeniz C, Mizrak Kaya D, Dilek O, Sungur MA, Bozkurt Duman B, Cil T. Efficacy of preoperative neutrophil-to-lymphocyte ratio in determining lymph node metastases in testicular cancer. Cukurova Medical Journal. 2021. 46(3):1070-1076.
10. Ozsener G, Mizrak Kaya D, Bakar Ates F. Elevated Endoglin Levels and Their Link to the Inflammatory Tumor Microenvironment in Colorectal Cancer. Journal of Faculty of Pharmacy of Ankara University. 2025. 49(3), 681-688.

• Kitap / Kitap Bölümleri

1. Mizrak D, İdilman R: Liver Transplantation. Liver Disease Patient Education Book, 2005, Ankara University Press
2. İdilman R, Mızrak D: Acute medical Disease and Pain. Medikal & Nobel Tıp Press 2010, pp.1607-1612, ISBN: 975-567-055-3, Turkey
3. Mızrak D, İdilman R: Scientific Research Support in Turkey. Bilimsel Tıp Press 2011, pp.209-217, Turkey
4. Mizrak D, Translation of the “Lung Cancer” Section into Turkish, The MD Anderson Manual of Medical Oncology
5. Mizrak D, İdilman R. Peptic Ulcer Bleeding. Turkiye Klinikleri Journal of Gastroenterohepatology Special Topics. 2008;1(2):10-13.
6. Mizrak D, İdilman R. Liver Transplantation: Patient selection, developing indications. Türkiye Klinikleri Journal of General Surgery Special Topics. 2009;2(1):10-14.
7. Mizrak D, Tüzün A, İdilman R. Hepatocellular Cancer Epidemiology and Risk Factors. Turkiye Klinikleri J Gastroenterohepatology Special Topics. 2014;7(2):1-6.
8. Konca Karabuga E, Mizrak Kaya D: Colorectal Cancer Management in Geriatric Patients. Current Treatments for Colorectal Cancer, Turkiye Klinikleri, DOI:5336/978-625-395-770-4_p171

• Bildiriler (Ulusal & Uluslararası Kongreler)

1. Toprak SK, Dalva K, Mizrak D, Arat M, Ozcan M, Gurman G, Ilhan O, Beksac M. Both Higher Level of (bcr,abl) Transcripts and High Hasford Risk Score Are Associated with Cytogenetic Response but Absence of Molecular Remission during First Line Use of Imanitib Mesilate(IM): A Finding Not Observed Following Use among Interferon Failures. ASH Annual Meeting 2004. San Diego, USA.
2. Idilman R, Mizrak D, Soykan I, Corapcioglu D, Erden E, Coban S, Bektas M, Uysal AR, Emral R, Doganay B, Ozden A. Insulin-sensitizer agents in the treatment of individuals with non-alcoholic steatohepatitis: a preliminary report. AASLD 2006. Boston, USA.
3. D, Idilman R, Bektas M, Erden E, Soykan I, Corapcioglu D, Doganay B, Emral R, Uysal AR, Ozden A. The effect of insuin-sensitizing agents in the treatment of individuals with non-alcoholic steatohepatitis. EASL 2007. April 12-16, 2007. Barcelona, Spain. (young investigator bursary)
4. Bozkus Y, Idilman R, Mizrak D, Cengiz G, Bektas M, Ustun Y, Cinar K, Ozden A. Lymphoproliferative disorders in chronic viral hepatitis. EASL 2008. April 23-27, 2008. Milan, Italy.
5. Idilman R, Seval G, Cinar K, Mizrak D, Bozkus Y, Arslan M, Bektas M, Erden E, Ozden A. The Effect of Dietary Intervention on the Long-Term Clinical Outcome of Non-Alcoholic Fatty Liver Disease. EASL 2009. April 22-26, 2009. Copenhagen, Denmark.
6. Karatayli SC, Mizrak D, Sayki M, Ozkan M, Erden E, Yurdaydin C, Idilman R, Bozdayi AM: Proteomic Biomarkers In Assessment of Liver Fibrosis Using SELDI-TOF MS. EASL 2009. April 22-26, 2009. Copenhagen, Denmark.
7. Arslan-Ergul A, Bagislar S, Konu O, Ozturk N, Ozdag H, Ozturk AR, Erdal E, Karademir S, Sagol O, Mizrak D, Bozkaya H, Bilen B, Ilk GH, Ilk O, Cetin-Atalay R, Ozturk M. A Major Role For Senescence And Immortality Gene Network In Hepatocellular Carcinoma. EASL 2009. April 22-26, 2009. Copenhagen, Denmark.
8. Yazihan N, Ataoglu H, Bozkaya H, Mizrak D, Onder FO, Yener B, Uzunalimoglu O. Significance of Elevated Midkine Levels in HBV-HCV Induced Cirrhosis and Hepatocellular Carcinoma. EASL 2009. April 22-26, 2009. Copenhagen, Denmark.
9. Idilman R, Seval G, Seven G, Cinar K, Mizrak D, Arslan M, Kabacam G, Ustun Y, Yakut M, Bektas M, Ozden A. The Characteristics and Natural Course of Non-Alcoholic Fatty Liver Disease in a Single Center Experience. EASL 2009. April 22-26, 2009. Copenhagen, Denmark.
10. Yildiz G, Bagislar S, Arslan-Ergul A, Gursoy-Yuzugullu O, Konu O, Yuzugullu H, Ozturk N, Ozdag H, Ozen C, Erdal E, Karademir S, Sagol O, Mizrak D, Bozkaya H, Ilk GH, Ilk O, Bilen B, Cetin-Atalay R, Akar N, Khochbin S, Ozturk M. A molecular signature of senescence escape in liver cancer. Les Journées de la Recherche médicale 2011. Grenoble, France.
11. Dede I, Utkan G, Akbulut H, Urun Y, Mizrak D, Icli F. Serum CEA and CA 15-3 levels according to breast cancer subtypes. 2013 ASCO Annual Meeting. May 31-June 04, 2013. Chicago/Illinois, USA.
12. Mizrak D, Araz M, Akbulut H, Kucuk NO, Alkan A, Yalcin S, Icli F. Correlation of tumor marker levels with intensity of FDG uptake on PET imaging in epithelial cancers. 2014 ASCO Annual Meeting. May 30-June 03, 2014. Chicago/Illinois, USA.
13. Alkan A, Mizrak D, Utkan G. Nutritional Status of Hospitalized Cancer Patients. ESMO 2014 Congress. Sep 26-30, 2014. Madrid, Spain.
14. Nebioglu S, Bakar F, Mizrak D, Icli F. Annexin V Expression and it’s Relation with Inflammatory Mediators in Colorectal Cancer Patients. 2014 World Cancer Congress. December 3-6, 2014. Melbourne, Australia.
15. Kantacioglu EO, Beton S, Tas V, Dursun G, Kaygusuz G, Mizrak D. Laryngeal Leiomyosarcoma: A Case Report with Review of the Current Litterature. 10th Congress of the European Laryngological Society. April 9-12, 2014. Antalya, Turkey.
16. Mizrak D, Onur H, Kubilay P, Ozturk B, Akbulut H. Blood Group: Is it associated with hormonal status, HER 2 status, and tumor grade in breast cancer? 14th St.Gallen International Breast Cancer Conference. March 18-21, 2015. Vienna, Austria.
17. Mizrak D, Onur H, Ozturk B, Kubilay P, Akbulut H. Effect of tumor hormonal and HER2 status on localization of metastases in recurrent breast cancer. 14th St.Gallen International Breast Cancer Conference. March 18-21, 2015. Vienna, Austria.
18. Mizrak D, Onur H, Kubilay P, Ozturk B, Gungor U, Akbulut H. Effect of HER 2 and hormonal status to FDG uptake on pet/ct imaging in recurrent breast cancer. 14th St.Gallen International Breast Cancer Conference. March 18-21, 2015. Vienna, Austria.
19. Mizrak D, Ozturk B, Kubilay P, Akbulut H, Onur H. More prognostic factors in early stage breast cancer. 14th St.Gallen International Breast Cancer Conference. March 18-21, 2015. Vienna, Austria.
20. Mizrak D, Ozturk B, Onur H, Kubilay P, Akbulut H. Serum levels of CEA and CA 15-3 in different subtypes of recurrent breast cancer. 14th St.Gallen International Breast Cancer Conference. March 18-21, 2015. Vienna, Austria.
21. Mizrak D, Kubilay P, Ozturk B, Onur H, Akbulut H. Preoperative systemic therapy for locally advanced breast cancer: Single center experience. 14th St.Gallen International Breast Cancer Conference. March 18-21, 2015. Vienna, Austria.
22. Akbulut H, Gercik O, Icli F, Mizrak D, Demirkazik A, Onur H, Cay Senler F, Utkan G. Sequential use of bevacizumab and cetuximab in patiemts with K-RAS wild type advanced colorectal cancer. 2015 ASCO Annual Meeting. June 3-7, 2015. Chicago/Illinois, USA.
23. Alkan A, Guc ZG, Senler FC, Yavuzsen T, Onur H, Dogan M, Karci E, Yasar A, Koksoy EB, Tanriverdi O, Turhal S, Urun Y, Ozkan A, Mizrak D, Akbulut H. Persistent postmastectomy pain syndrome and posttraumatic stress disorder (ORTHUS study): a study of the palliative care working committee of the Turkish Oncology Group (TOG). 2016 ASCO Annual Meeting. June 3-7, 2016. Chicago/Illinois, USA.
24. Shimodaira Y, Slack RS, Chen HC, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Harada K, Amlashi FG, Mizrak D, Blum MA, Roth JA, Swisher S, Skinner HD, Hofstetter WL, Komaki R, Walsh GL, Ajani JA. Influence of induction chemotherapy (IC) in trimodality-eligible esophageal cancer patients: Secondary analysis of a randomized trial. 2016 ASCO Annual Meeting. June 3-7, 2016. Chicago/Illinois, USA.
25. Alkan A, Mizrak D, Karci E, Yasar A, Koksoy EB, Urun M, Kutuk T, Urun Y, Cay Senler F, Akyurek S, Utkan G, Demirkazik A, Gokce SC, Akbulut H. Adjuvant concurrent chemoradiotherapy (CRT) plus docetaxel-cisplatin-fluorouracil (DCF) versus CRT plus fluorouracil folinic acid (FUFA) in gastric cancer. ESMO 2016 Congress. Oct 7-11, 2016. Copenhagen, Denmark.
26. Mizrak Kaya D, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A, Sagebiel TL, Skinner HD, Wu CC, Hofstetter WL, Badgwell BD, Ajani JA. Long-term survival in 101 metastatic gastroesophageal cancer (mGEAC) patients eventually treated with consolidative local therapy. 2017 Gastrointestinal Cancers Symposium. January 19-21, 2017. San Francisco/CA, USA.
27. Mizrak Kaya D, Nogueras-Gonzalez GM, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Wu CC, Matamoros A, Sagebiel TL, Mansfield PF, Badgwell BD, Ajani JA. Risk of peritoneal carcinomatosis in localized gastric adenocarcinoma patients who undergo preoperative therapy and attempted surgery. 2017 Gastrointestinal Cancers Symposium. January 19-21, 2017. San Francisco/CA, USA.
28. Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Lin Q, Blum Murphy MA, Maru DM, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA. Metabolic activity predicts clinical response and prognosis in esophageal adenocarcinoma patients treated with bimodality. 2018 Gastrointestinal Cancers Symposium. January 18-20, 2018. San Francisco/CA, USA.
29. Mizrak Kaya D, Nogueras-Gonzalez GM, Estrella JS, Harada K, Amlashi FG, Lin Q, Blum Murphy MA, Lee JH, Weston B, Bhutani MS, Matamoros A, Sagebiel TL, Devine CE, Patnana M, Minsky BD, Das P, Badgwell BD, Ajani JA. Potentially curable gastric adenocarcinoma (GAC) patients treated without surgery. 2018 Gastrointestinal Cancers Symposium. January 18-20, 2018. San Francisco/CA, USA.
30. Samdani RT, Mizrak Kaya D, Blum Murphy MA, Badgwell BD, Katz MH, Rashid A, Estrella JS. Gastric Carcinoma Post Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A case series. 2018 USCAP (United States and Canadian Academy of Pathology) Annual Meeting. March 17-23,2018. Vancouver/BC, Canada.
31. Mizrak Kaya D, Nogueras-Gonzalez GM, Estrella JS, Harada K, Amlashi FG, Lin Q, Blum Murphy MA, Lee JH, Weston B, Bhutani MS, Matamoros A, Sagebiel TL, Devine CE, Patnana M, Minsky BD, Das P, Badgwell BD, Ajani JA.Efficacy of three-drug induction chemotherapy followed bypreoperative chemoradiation in patients with localized gastric adenocarcinoma (GAC). 2019 Gastrointestinal Cancers Symposium. January 17-19, 2019. San Francisco/CA, USA.
32. Baskurt K, Sutcuoglu O, Mizrak Kaya D. FOLFOX as a therapeutic option in patients with hepatic failure due to liver metastasis of gastrointestinal (GI) system malignancies: A case series. 2024 ASCO Annual Meeting. May 31-June 4, 2024. Chicago/Illinois, USA.
33. Ismail Dilli, Osman Sütcüoğlu, Ozlem Aydin Isak, Gizem Kavak, Goksen Inanc Imamoglu, Dogan Yazilitas, Bülent Aksel, Ferit Aydin, Abdullah Senlikci, Mustafa Taner Bostanci, Semra Demirtas Senlik, Sehnaz Evrimler, Ata Turker Arikok, Yildiz Guney, Guler Yavas, Dilsa Mizrak Kaya. Effect of chemoradiation followed by surgery on outcomes compared to definitive chemoradiation in locally advanced esophageal squamous cell carcinoma: A single-center experience. 2025 ASCO Annual Meeting. May 31-June 4, 2025. Chicago/Illinois, USA.
34. Selahattin Celik, Osman Sütcüoğlu, Kadriye Başkurt, Ozlem Aydin Isak, Semra Demirtas Senlik, Ata Turker Arikok, Sehnaz Evrimler, Berna Oksuzoglu, Dilsa Mizrak Kaya. Vitamin D serum level as a predictor of response to immunotherapy for non-small cell lung cancer. 2025 ASCO Annual Meeting. May 31-June 4, 2025. Chicago/Illinois, USA.
35. DC Guven, TK Sahin, I Eroglu, I Dilli, O Sutcuoglu, E Chalabiyev, BY Aktas, D Mizrak Kaya, O Ates, N Ozdemir, S Yalcin, O Dizdar. Induction chemotherapy followed by definitive chemoradiation in patients with inoperable esophageal squamous cell carcinoma: A multicenter retrospective study. 2025 ESMO Gastrointestinal Cancers Congress.2-5 July,2025. Barcelona, Spain.
36. BB Karaoglan, M Mehdiyev, S Kaya, FT Kos, D Mizrak Kaya, P Kubilay Tolunay. Prognostic significance of HER2-low status in advanced gastric cancer. 2025 ESMO Gastrointestinal Cancers Congress.2-5 July,2025. Barcelona, Spain.
37. Dilsa Mizrak Kaya, Aparna Kalyan, Sukeshi Patel Arora, Raed Al-Rajabi, Tarik Demir, Laura M. Kulik, Chengwei Peng, Mary F Mulcahy, Al Bowen Benson III, Ruohui Chen, Devalingam Mahalingam. A phase Ib/II study of zanzalintinib (XL092) in second line and beyond for the treatment of advanced hepatocellular carcinoma. 2026 Gastrointestinal Cancers Symposium. January 8-10, 2026. San Francisco/CA, USA.
38. Dilsa Mizrak Kaya, Yangruijue Ma, Tarik Demir, Aparna Kalyan, Sheetal Kircher, Mary Mulcahy, Al B. Benson III, Ruohui Chen, Devalingam Mahalingam. KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trial. 2026 American Association for Cancer Research (AACR) Annual Meeting. April 17-22, 2026. San Diego/CA, USA.